KYAN harnesses its powerful technology platforms to transform the way that patients are treated.

KYAN completely de-risks the drug development process, resulting in powerful and proprietary new combination therapies, as well as individualized treatment with unprecedented efficacy and safety.


Drug Development

KYAN has a pipeline of clinical-stage therapies optimized by our technology platforms. De-risked, optimized and proprietary drug development enabled by technology.

Personalized Medicine

We have clinically tailored treatment for some of the major diseases of our generation using the our platforms. Actionable therapy.



KYAN believes that everyone should have the opportunity to join the fight against orphan and other serious diseases. With KYAN, now they can.


Dean Ho, Ph.D., KYAN Chief

Drug development leader. Nanomedicine visionary. Fellow, AIMBE.

Chih-Ming Ho, Ph.D., KYAN Technology Guru

PPM Pioneer. Engineering rockstar. Member, US National Academy of Engineering.

Edward K. Chow, Ph.D., KYAN Drug Development Guru

Cancer research phenom. Winner, Northwestern Venture Comp. Mixed Martial Artist.

Xianting Ding, Ph.D., KYAN Strategy Guru

Hospital alliance builder. Infectious diseases warrior. Slam dunker. 


Dean Ho, Ph.D., KYAN Chief

Dr. Ho is Professor of Bioengineering at UCLA and was previously the President of the SLAS Board of Directors, working with leading figures in pharma, medical devices, and academia on global expansion and strategic initiatives for a 22,000-member society. Dr. Ho is a Co-Founder of RAEN Biotech, and serves on the advisory boards of Q Venture Partners, Bikanta (Y-Combinator) and Sintact Medical Systems.  He is a Fellow of the American Institute of Medical and Biological Engineering and Society for Laboratory Automation and Screening. Dr. Ho was recently named to the 2016 Power List of Pathologist Magazine. 

Roy Doumani, J.D., M.B.A., Director

Mr. Doumani is the Vice Chairman of Xiamen International Bank (XIB) and was Founder and Director of First Los Angeles Bank. Mr. Doumani is currently on the Board of Directors of KITE Pharma, and is Chairman of the Board of Neural Analytics. He has served as a board member and advisor to companies in the United States, Asia and Europe, including serving as the Vice Chairman of CTI (CTMI NASDAQ-listed). Mr. Doumani was recently featured among the Los Angeles Business Journal 500.


J. Michael Bishop, M.D.

Dr. Bishop is a recipient of the 1989 Nobel Prize in Medicine or Physiology for his discovery of the cellular origins of the retroviral oncogene. Specifically, he discovered the first human oncogene, c-Src, which served as a foundation for understanding how malignant tumors are formed. He is Chancellor-Emeritus of the University of California, San Francisco, and the Director of the G.W. Hooper Foundation. He is a member of the National Academy of Sciences and National Academy of Medicine. He is also a recipient of the National Medal of Science in 2003. 


Wee Joo Chng, M.D.

Dr. Chng is the Director of the National University Cancer Institute, Singapore. He is also the Head of the National University Cancer Institute Division of Haematology-Oncology, Deputy Director of the Cancer Science Institute of Singapore, and Leader of the Haematologic Malignancy Tumour Group of the National University Cancer Institute. His team has played a leading role in developing novel treatment strategies for haematological malignancies. He is a recipient of the NMRC Clinician Scientist Award.


Ali Zarrinpar, M.D., Ph.D.

Dr. Zarrinpar is a liver transplant surgeon at the UCLA Division of Liver and Pancreas and Transplantation and Dumont-UCLA Liver Transplant Center, widely regarded as among the world's pre-eminent transplant programs. He is the Director of the UCLA Liver Tissue Bank and Ischemia/Reperfusion Tissue and Blood Repository. He is an internationally-recognized researcher and has led numerous clinical studies examining novel therapies and technologies towards improved patient outcomes in liver disease and transplantation.